Spine-Related Health Care Utilization and Costs Following Orthobiologic Injection Versus Lumbar Surgery for Degenerative Spine Conditions

In a retrospective study of adults with degenerative spine conditions meeting surgical criteria, platelet-rich plasma (PRP) injections were associated with significantly lower healthcare utilization and costs compared to lumbar fusion or decompression surgery over 24 months, without evidence of increased subsequent surgery rates.

The Gist

Imagine your spine is like the central support beam of an old, creaky house. Over time, the wood rots (degenerative disc disease), and the house starts to sag. You have two main options to fix it:

1. The "Surgical Renovation" (Spine Surgery): You tear out the damaged beams, weld in new steel supports (fusion), or cut away the rotting wood to make space (decompression). It's a big, loud, expensive construction project. It fixes the problem fast, but it's invasive, takes months to recover, and sometimes the house still creaks later, requiring more work.
2. The "Biological Repair Kit" (Orthobiologics/PRP): Instead of replacing the beam, you inject a special "super-sealant" made from your own blood (Platelet-Rich Plasma or PRP). This sealant is designed to tell your body to heal the rot itself. It's less invasive, like patching a hole in a tire rather than buying a whole new one.

The Big Question:
For years, doctors and insurance companies have worried that the "Biological Repair Kit" is just a temporary bandage. They feared: "If we let people use the sealant, they'll just delay the inevitable surgery, spend money on the sealant, and then still have to pay for the big renovation later. We'll end up paying for both!"

This study set out to settle that debate.

The Experiment: A Race Between Two Groups

The researchers looked at thousands of people with bad backs who were told they needed surgery. They split them into two matched groups (like twins in a race):

• Group A: Got the big "Surgical Renovation."
• Group B: Got the "Biological Repair Kit" (PRP injections).

They then tracked these two groups for up to 4 years, looking at two things:

1. Did Group B eventually have to get the surgery anyway? (The "Delay" Fear)
2. Who spent more money? (The "Cost" Fear)

The Results: The Surprise Winner

1. Did the "Sealant" just delay the surgery?
No. This was the biggest surprise.
People who got the PRP injections were not rushing to get surgery later. In fact, very few of them ever needed the big renovation at all.

• Analogy: It's like putting a high-quality patch on a tire. You don't end up buying a new car two years later because the patch failed; the patch actually held up. The study found that the PRP group didn't "fail" and run to the surgeon; they stayed on the PRP path.

2. Who spent more money?
The Surgery Group spent way more.
Even though the surgery fixes the problem immediately, the total cost over two years was much higher for the surgery group.

• Why? Surgery is expensive upfront (the operating room, the hospital stay). But the real cost killer was the "aftermath." Surgery patients needed more home health nurses, more X-rays, more follow-up visits, and more physical therapy to recover.
• Analogy: Think of it like buying a cheap, low-maintenance car (PRP) versus a luxury sports car (Surgery). The sports car looks cool and fast, but it costs a fortune in gas, insurance, and repairs every month. The study showed that the "sports car" (surgery) cost the insurance companies roughly $28,000 to $66,000 more over two years than the "reliable sedan" (PRP).

The Catch (Limitations)

The authors are honest about the flaws in their study:

• Selection Bias: The people who chose PRP might have been slightly different to begin with (maybe they were younger or had less severe pain). It's like comparing a marathon runner to a casual jogger; the runner might naturally do better regardless of the shoes.
• No "Pain Score": The study looked at money and hospital visits, but it didn't ask the patients, "Does your back hurt less?" We know the money saved, but we don't have a perfect scorecard on how happy the patients were.
• Data Gaps: Some data was hidden to protect privacy, so the numbers for the PRP group are a bit fuzzy.

The Bottom Line

For people with degenerative spine conditions who are candidates for surgery, this study suggests that trying the "Biological Repair Kit" (PRP) first is a smart, cost-effective move.

It doesn't seem to be a "delay tactic" that wastes money. Instead, it appears to be a legitimate alternative that saves the healthcare system a fortune and spares patients the trauma of a major surgery, without forcing them to go back for the big operation later.

In short: Sometimes, the "patch" works just as well as the "replacement," and it costs a lot less to keep the house standing.

Technical Summary

1. Problem Statement

Lumbar fusion and decompression procedures (laminectomy, foraminotomy, discectomy, and facetectomy, collectively LFDF) are standard treatments for degenerative spine conditions but are associated with high healthcare costs, variable outcomes, and significant risks (e.g., infection, nerve injury, chronic postsurgical pain). While orthobiologic therapies, specifically Platelet-Rich Plasma (PRP) and Bone Marrow Aspirate Concentrate (BMAC), have emerged as less invasive alternatives, there is limited real-world evidence regarding their comparative effectiveness and economic impact.

A primary concern among payers and clinicians is that orthobiologics might merely delay inevitable surgery, thereby increasing total healthcare utilization and costs through repeat injections and adjunctive services without preventing the eventual need for surgical intervention. This study aims to fill that evidence gap by comparing spine-related healthcare utilization and aggregate costs between patients receiving PRP and those undergoing surgery.

2. Methodology

Study Design:

• Type: Retrospective, observational study.
• Data Sources: Linked commercial insurance claims data (nationwide provider) and the Regenexx patient registry (for orthobiologic procedure details).
• Timeframe: Procedures performed between 2016 and 2023.

Study Population & Eligibility:

• Inclusion: Adults (≥18 years) with commercial insurance, diagnosed with lumbar degenerative disc disease (DDD) or related conditions (spondylosis, spondylolisthesis, stenosis, radiculopathy), and meeting criteria for either lumbar fusion, LFDF, or PRP injection.
• Exclusion: Inflammatory syndromes, traumatic injuries, bone cancer, prior spinal surgery/radiofrequency ablation, or recent corticosteroid use (for PRP cohort).
• Cohorts:
  1. PRP vs. Fusion: Patients eligible for both.
  2. PRP vs. LFDF: Patients eligible for both.

Statistical Analysis:

• Propensity Score Matching (PSM): A 1:20 greedy matching algorithm was used to balance cohorts on demographics, comorbidities, spine diagnoses, prior healthcare use, and severity proxies.
• Outcomes:
  • Primary: Aggregate healthcare costs at 12 and 24 months post-procedure.
  • Secondary: Healthcare Resource Utilization (HCRU) including imaging, outpatient visits, home health, physical therapy, opioid use, and subsequent surgeries.
  • Exploratory: Outcomes at 36 and 48 months.
• Costing Models: Four methods were applied:
  1. External Medicare rates.
  2. Medicare rates × 2 (approximate private payer multiplier).
  3. Commercial payer average allowed amounts.
  4. Aggregate costing (sum of actual commercial claims, with truncation at 5th/95th percentiles to handle outliers).

3. Key Contributions

• Real-World Evidence: This is one of the few studies linking a national orthobiologic registry with commercial claims to provide a large-scale, real-world comparison of orthobiologics versus surgery.
• Rigorous Matching: The use of extensive propensity score matching (1:20 ratio) created highly balanced cohorts, mitigating selection bias to a degree not previously achieved in this specific comparison.
• Multi-Method Costing: By applying multiple costing methodologies (Medicare-based, commercial average, and aggregate), the study ensures robustness in economic conclusions regardless of the specific payer model.
• Longitudinal Analysis: The study extends beyond the immediate post-operative period, analyzing utilization and costs up to 48 months.

4. Key Results

Sample Characteristics:

• PRP vs. Fusion: 133 PRP patients matched to 2,560 fusion patients.
• PRP vs. LFDF: 198 PRP patients matched to 3,960 LFDF patients.
• Balance: Post-matching, all demographic and clinical variables were well-balanced (Absolute Standardized Mean Differences < 0.10), except for pre-operative imaging (which is inherently bundled with surgical planning).

Healthcare Utilization (HCRU):

• Progression to Surgery: Rates of subsequent spine surgery (fusion or LFDF) following PRP were below the cell suppression threshold (<11 events) at 12, 24, 36, and 48 months. In contrast, surgical cohorts had reoperation rates of 7.4–9.3% (fusion) and 21.8–23.7% (LFDF) at 24 months.
• Imaging & Home Health: Surgical cohorts had significantly higher rates of post-procedure radiographs and home health services compared to PRP cohorts.
• Outpatient Visits:
  • PRP vs. Fusion: Fusion patients had higher outpatient visit rates (5.9 vs 4.6 at 12 months).
  • PRP vs. LFDF: PRP patients had higher outpatient visit rates at 12 months (4.5 vs 3.2), but this trend reversed at 24 months (7.9 vs 5.3), with PRP patients having higher utilization.
• Opioids & PT: No consistent significant differences were found in opioid use or physical therapy utilization between groups.

Costs:

• PRP vs. Fusion: Surgery was significantly more expensive across all costing methods.
  • 12-month mean difference: $28,454 to $66,756 higher for fusion.
  • 24-month mean difference: $28,914 to $66,756 higher for fusion.
• PRP vs. LFDF: Surgery was generally more expensive, though the gap was smaller than in fusion comparisons.
  • 12-month mean difference: $2,579 to $17,944 higher for LFDF.
  • 24-month mean difference: $2,488 to $17,931 higher for LFDF (except for the aggregate method where the difference was not statistically significant, p=0.09).
• Drivers of Cost: The primary cost drivers for surgery were the index procedure costs and higher rates of reoperation and imaging.

5. Significance and Limitations

Significance:

• Cost-Efficiency: For select patients meeting surgical criteria, PRP is associated with substantially lower aggregate healthcare costs (up to ~$66k savings vs. fusion at 24 months) without evidence of increased downstream surgical utilization.
• Clinical Value: The low rate of subsequent surgery in the PRP group challenges the hypothesis that orthobiologics merely delay inevitable operations.
• Policy Implications: Findings support the consideration of orthobiologic options as a viable, cost-conscious alternative for appropriately selected patients, potentially reducing the burden on healthcare systems.

Limitations:

• Selection Bias: Despite PSM, unmeasured confounders (e.g., pain intensity, mental health, work status) may influence treatment choice and outcomes. Patients choosing PRP may have a lower overall disease burden.
• Data Granularity: The study relies on claims data; patient-reported outcomes (PROs) and detailed imaging findings were not available.
• Generalizability: The PRP cohort was younger (mean age ~50–53) than typical surgical populations, and the study did not include standardized protocols for orthobiologic preparation.
• Cell Suppression: Privacy protections required suppressing data for small cell counts (<11), limiting the precision of rare event analysis (e.g., specific reoperation rates in the PRP group).

Conclusion:
The study suggests that for a specific subset of patients with degenerative spine conditions, orthobiologic injections (PRP) offer a cost-effective alternative to surgery with lower healthcare utilization and no apparent increase in the rate of subsequent surgical intervention over a 2-year period. Further prospective research with patient-reported outcomes is recommended to confirm these findings.